David Sze

Source: Wikipedia, the free encyclopedia.
David Sze
Entrepreneur
  • Investor
  • David Sze is an American entrepreneur, investor, and managing partner at the venture capital firm Greylock Partners. Sze was named to Forbes' Midas List in 2013 and 2014.[1][2]

    Career

    Excite, Inc.

    Before joining Greylock Partners in 2000, Sze was SVP of Product Strategy at Excite and then Excite@Home. Prior roles at Excite included general manager of Excite.com and vice president of Content and Programming for the Excite Network.[citation needed]

    Greylock Partners

    Sze joined Greylock in 2000, as a result of his involvement in consumer companies,[3] Greylock moved their headquarters from Boston to Silicon Valley’s Sand Hill Road.[4] Sze led early investments in companies including Facebook, Pandora, LinkedIn, Workday, and Palo Alto Networks.[citation needed] In 2013, Sze and Reid Hoffman announced Greylock's 14th fund of $1 billion.[5]

    Sze has previously invested in NOCpulse,[6] New Edge Networks, Oodle, Revision3, SGN, SoftCoin , VUDU, and Digg, all of which have been acquired by larger companies.[citation needed]

    Personal life

    His sister is artist Sarah Sze.[7] His grandfather Szeming Sze was involved in establishing the U.N.'s World Health Organization.[citation needed]

    References

    1. ^ "The Midas List Tech's Top Investors". Forbes.
    2. ^ "Midas List 2013: The Top 10". Forbes. Archived from the original on June 7, 2013.
    3. ^ Shah, Semil. "A Career Of Company Building: Text Of My Discussion With David Sze". Haywire. Retrieved 2 October 2013.
    4. ^ Stone, Brad. "Venture Firm Greylock Partners Outshines Silicon Valley Rivals". BloombergBusinessweek. Archived from the original on July 28, 2013. Retrieved 18 July 2013.
    5. ^ Primack, Dan. "Greylock raises $1 billion to find the next LinkedIn". Fortune. Archived from the original on 11 September 2013. Retrieved 10 September 2013.
    6. ^ Rooney, Paula (15 October 2002). "Red Hat Confirms Acquisition Of NOCpulse". CRN.
    7. ISSN 0029-7712
      . Retrieved 2023-10-18.